



JAPAN TOBACCO INC.
2-1, Toranomom 2-chome, Minato-ku
Tokyo 105-8422 JAPAN
Phone:03-3582-3111

FOR IMMEDIATE RELEASE

Tokyo, December 6, 2012

New Drug Application for marketing approval of a novel anti-HIV single tablet regimen containing JTK-303 (elvitegravir) in Japan filed by JT

Tokyo, December 6, 2012 --- Japan Tobacco Inc. (JT) (TSE:2914) announced today that the Company has filed a New Drug Application (NDA) for marketing approval of a novel anti-HIV single tablet regimen containing JT's original compound JTK-303 (elvitegravir) with the Japanese Ministry of Health, Labour and Welfare.

The complete, once-daily, single-tablet regimen contains elvitegravir, an integrase inhibitor; cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of elvitegravir; emtricitabine (Emtriva[®] 200mg capsule) and tenofovir disoproxil fumarate (Viread[®] 300mg tablet). The U.S. Food and Drug Administration (FDA) has approved this fixed-dose, single-tablet regimen, Stribild[™] as its product name, on August 27, 2012, which was filed by Gilead Sciences, Inc. (Gilead). JT licensed elvitegravir to Gilead in 2005 with exclusive rights to develop and commercialize the drug worldwide, excluding Japan.

If approved, the product would be the only once-daily, single-tablet regimen to be commercialized in Japan. While combination antiretroviral therapy has been a standard of care for HIV infection, this single-tablet regimen is expected to provide patients' convenience and long-term drug adherence.

Under the terms of the agreement with Torii Pharmaceutical Co., Ltd. (Torii), JT's pharmaceutical subsidiary, on August 28, 2012, Torii has exclusive rights to commercialize the drug in Japan, upon marketing approval.

* JTK-303 (elvitegravir) and cobicistat as standalone agents are investigational products and their safety and efficacy have not yet been established worldwide, including in Japan.

* Emtriva, Viread and Stribild are trademarks or registered trademarks of Gilead Sciences, Inc.

###

Japan Tobacco Inc. is a leading international tobacco product company. Its products are sold in over 120 countries and its internationally recognized cigarette brands include Winston, Camel, Mild Seven and Benson & Hedges. With diversified operations, JT is also actively present in pharmaceuticals and foods. The company's revenue were ¥2.034 trillion (US\$24,745 million()) in the fiscal year ended March 31, 2012.*

**Translated at the rate of ¥82.19 per \$1, as of March 31, 2012*

Contacts: Hideyuki Yamamoto, General Manager
Ryohei Sugata, Associate General Manager
Media and Investor Relations Division
Japan Tobacco Inc.
Tokyo: +81-3-5572-4292
E-mail: jt.media.relations@jt.com